News

Featured news

21 Sep 2026 1 min read

MST Access research report

MST Access has published a research report on Lumos Diagnostics Limited.

Read article

16 Sep 2026 2 min read

FebriDx® Commercial Traction Continues to Advance

Lumos Diagnostics has announced further progress in the U.S. commercialisation of FebriDx® across its priority top-100 urgent care target list.

Read article

12 Jun 2026 1 min read

REPLAY | FebriDx US Launch Update

Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales

Read article

All news

13 Dec 2023 1 min read

CBS News | CDC warns overuse of antibiotics may cause antimicrobial-resistant infections

The Center for Disease Control has warned of the dangers of antibiotic overuse, which can make...

Read article

11 Sep 2023 2 min read

US FDA Grants Emergency Use Authorization For ViraDx™

Lumos Diagnostics (ASX: LDX) had today announced that the US Food...

Read article

30 Jul 2023 1 min read

USA Today | Not 'if' but 'when': Antibiotic resistance poses existential threat for modern medicine

Lumos’ FebriDx test has been identified as a useful tool in the fight to ‘outsmart’ antimicrobial...

Read article

03 Jul 2023 3 min read

Lumos Receives US FDA Clearance for FebriDx®

Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care...

Read article

21 Jun 2022 2 min read

Lumos Diagnostics Appoints Doug Ward As CEO

Ward to lead U.S. FebriDx launch pending FDA 510(k) clearance...

Read article

06 Oct 2021 2 min read

Economic Evaluation of Lumos Diagnostics’ FebriDx Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually

Lumos Diagnostics (ASX: LDX) has today announced that the Journal of Health Economics...

Read article